

Patient screening common among Nova Scotia FPs

'Meet-and-greet' sessions are permissible, but ethically risky

BY PAULINE ANDERSON
Halifax

Dr. Emily Marshall (PhD) knows what it's like to be turned down by a family physician. In fact, it happened to her not just once, but on multiple occasions.

When she moved to Halifax from Vancouver, it took Dr. Marshall, who is now an assistant professor in the department of family medicine at Dalhousie University, three years to find a family doctor who would accept her as a patient. And that was only after she attended a so-called "meet-and-greet" session with her prospective provider, before which she recalls being "really nervous."


Even though meet-and-greets are being discouraged in many parts of the country, and there's mounting concern they are being used to screen unwanted or difficult patients, such sessions are being held by almost one-third of primary-care physicians in Nova Scotia, a new survey shows.

"My concern is that meetings like this can be interpreted by the public as discriminatory, regardless of the true intentions of the health-care provider," said Dr. Marshall, who led the study and presented it recently at the North American Primary Care Research Group meeting in New York.

"I suspect the vast majority of these (meetings) are innocently done by doctors trying to make sure that there's a good fit with a patient, but I also think that the potential is there for it to be unethically applied and to leave the most vulnerable people at risk of not finding a regular provider."

Dr. Marshall and her colleagues surveyed primary-care practices across Nova Scotia. They asked about whether the practice was accepting new patients and if it wasn't, whether there were ever any exceptions. Of 741 practices, they got completed surveys from 628 providers, including 589 family physicians and 39 nurse practitioners. This represented a response rate of 85%. The survey is part of the Models and Access to Primary Care in Nova Scotia (MAAP-NS) study.

According to the survey, 29.2% of respondents said they require a screening



College policy states that practitioners should not screen out patients with more difficult health concerns.

appointment for new patients and 44.3% of these providers reported that on at least one occasion they didn't continue to see a patient after such a meeting. At the same time, though, 36.9% of providers requiring a meet-and-greet reported that a patient subsequently decided not to continue in the practice on at least one occasion.

'Ethical quandary'

Dr. Marshall said she was "surprised" by the "higher than expected" rate of doctors asking patients to come in for some type of screening appointment.

What happens during these pre-acceptance visits? "It's a bit of a black box," commented Dr. Marshall. "Different clinicians have different perspectives on this. Some think it's a sacred thing to be able to meet with patients, to get to know them and build that relationship, and to make sure it's a good fit; others see this as a real ethical quandary."

There have been increasing reports in the media about this meet-and-greet practice and even some court cases challenging it, said Dr. Marshall.

In the current climate where fewer physicians are accepting new patients, some patients fear they won't find a regular provider. "I worry that it would lead to patients potentially not disclosing their actual health concerns or their risk behaviours" for example, their smoking or gambling habits, said Dr. Marshall.

"I can't find a lot of reasons why you would need to screen people out," added Dr. Marshall, who wondered why the initial meeting with patients can't be done after accepting them into the practice.

According to the Nova Scotia Human Rights Act, doctors can't discriminate based on,

for example, age, gender, race, sexual orientation or disability. However, they can refuse a patient whose needs are beyond the scope of their practice. Doctors in teaching hospitals can also deny accepting patients who refuse to be seen by medical students, according to Dr. Marshall.

Some provincial colleges of physicians and surgeons have taken a strong stand on this issue. For example, according to Dr. Marshall, after holding a public consultation on the matter, the Ontario college issued a statement saying that doctors should provide care on a first-come, first-served basis and that there should be no meet-and-greet sessions "as it's too challenging to know whether they are being done ethically."

College policy

The College of Physicians and Surgeons of Nova Scotia also advocates accepting patients on a first-come, first-served basis. In a statement on its website, it says that while initial appointments and health status questionnaires are acceptable practice for physicians to get to know new patients and to learn of their health concerns and history, "these may not be used to select 'easy patients' and/or to screen out those with more difficult health concerns, such as chronic or terminal disease."

The college's policy, according to registrar Dr. Gus Grant, provides "clear guidance" for physicians. "Meet-and-greet interviews are permissible, but obviously fraught with potential problems."

The new study is "an eye opener," he said. "It certainly gives us in the regulatory world pause."

He added that it's helpful to know the prevalence of the meet-and-greet practice.

"It gives us an opportunity to repeat the message and under-ethics that must underpin the meet-and-greet meeting."

What's unfortunately not immediately apparent from the study, though, are the reasons for the results, he said. As well, he added, the study doesn't indicate "what the right number

should be in a perfect world."

The survey also found that doctors do make exceptions on accepting new patients when it comes to family members.

Unhelpful offices

Dr. Marshall also presented the results of another survey that is part of the MAAP-NS study. Investigators called 394 family

 **Cymbalta**[®] DELAYED RELEASE CAPSULES
duloxetine HCl

Indications and clinical use

- Cymbalta[®] (duloxetine hydrochloride) is indicated for:
 - the symptomatic relief of major depressive disorder (MDD)
 - the symptomatic relief of anxiety causing clinically significant distress in patients with generalized anxiety disorder (GAD)
- The efficacy of Cymbalta[®] in maintaining anxiolytic response for up to 6 months in patients with GAD was demonstrated in a long-term placebo-controlled trial in patients who had initially responded to Cymbalta[®] during a 6-month open-label phase.
- Cymbalta[®] is not indicated for use in children under 18 years of age.

Contraindications

- Patients concomitantly taking any of the following medications: monoamine oxidase inhibitors (MAOI), including linezolid and methylene blue, or within at least 14 days of discontinuing treatment with an MAOI; potent CYP1A2 inhibitors (e.g. fluvoxamine) and some quinolone antibiotics (e.g. ciprofloxacin or enoxacin); and thioridazine
- Any liver disease resulting in hepatic impairment
- Uncontrolled narrow-angle glaucoma
- End-stage renal disease (requiring dialysis) or patients with severe renal impairment (estimated creatinine clearance <30 mL/min)

Most serious warnings and precautions

- Behavioural and emotional changes, including self-harm: SSRIs and other newer antidepressants may be associated with:
 - Behavioural and emotional changes, including an increased risk of suicidal ideation and behaviour in patients <18 years
 - Severe agitation-type adverse events coupled with self-harm or harm to others in patients of all ages
 - Rigorous clinical monitoring for suicidal ideation and behaviour and agitation-type emotional and behavioural changes is advised in patients of all ages
 - Increased risk of suicidal behaviour in patients ages 18 to 24 years with psychiatric disorder
- Discontinuation symptoms: Cymbalta[®] should not be discontinued abruptly. A gradual dose reduction is recommended.

Other relevant warnings and precautions

- Cymbalta[®] should not ordinarily be prescribed to patients with substantial alcohol use as it may be associated with severe liver injury.
- Investigate symptoms of liver damage promptly. Discontinue and do not re-start in patients with jaundice.
- Bone fracture risk with SSRIs/SNRIs
- Risk of increases in blood pressure and heart rate. Monitor as necessary.
- Risk of hypertensive crisis in uncontrolled hypertension
- Abnormal bleeding risk with SSRIs/SNRIs
- Caution of increased bleeding events concomitant use of NSAIDs, ASA, or other drugs affecting coagulation
- Risk of serotonin syndrome or neuroleptic malignant syndrome-like reactions
- Risk of urinary hesitation and retention
- Risk of serious skin reactions, including Stevens-Johnson syndrome and erythema multiforme
- Akathisia/psychomotor restlessness
- Caution is advisable when using Cymbalta[®] in patients with diseases or conditions that produce altered metabolism or hemodynamic responses (e.g. conditions that slow gastric emptying).
- Patients with history of drug abuse
- Worsened glycaemic control in some diabetic patients
- Hyponatremia associated with SSRIs and SNRIs
- Patients with a history of seizure disorder
- Patients with raised intraocular pressure or those with narrow-angle glaucoma
- Patients with a history of mania
- Effect on ability to drive and use machines
- Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrose-isomaltase insufficiency should not take this medicine.

For more information

Please consult the product monograph at www.lilly.ca/cymbaltapm/en for important information relating to adverse reactions, drug interactions, dosing and administration which have not been discussed in this piece.

The product monograph is also available by calling 1-866-364-4043.

A serotonin-norepinephrine reuptake inhibitor (SNRI) also indicated for the symptomatic relief of

Major Depressive Disorder (MDD)¹

practices and acted out scenarios that represented two socioeconomic circumstances (the caller had just moved to take up a new job at a bank or the caller had been told to call by a welfare worker), and two types of patients (the caller needed a doctor for regular care or the caller needed an appointment because their asthma was acting up).

Dr. Marshall noted it was difficult to even reach some doctors' offices by phone. Callers were unable to reach 25 offices, despite five attempts.



Meetings like this can be interpreted by the public as discriminatory.

—Dr. Emily Marshall (PhD)

From those that did respond, the investigators found that socioeconomic status and the presence of a chronic condition were not correlated with being offered

an appointment. However, only 24.4% of offices provided further assistance to those not offered an appointment, and of these, 60.6% were patients of higher and 39.4% lower

socioeconomic status.

"Provider offices could do a lot more to support orphaned patients," said Dr. Marshall. "They could refer them to walk-in clinics and regional health authorities who have phone lines to help place these patients, but these resources were rarely shared at all and they were less frequently shared if you were of low socioeconomic status.

"Our callers were often made to feel like they were a hassle to the person they were calling." MP

Clinical Pearls

Dose by weight in kids—and write it down



Using a child's age for dosing is an easy way to get it wrong.

ONE OF MY PATIENTS

showed me a picture from her phone of her 11-year-old son at soccer practice standing with another friend of the same age. Her son was a full two heads taller than his friend and about that larger in girth, too. Conversely, my son was denied access to several rides at a travelling fair this summer when the top of his head failed to reach the procrustean two-year-old height marker—he was two-and-three-quarter years old at the time.

These two examples illustrate why I insist on writing children's weights onto the prescriptions that I write for them. Dosing by age is an easy way to over- or undermedicate our pediatric patients. There is too much variability in size between children of identical ages for me to feel comfortable with rules of thumb like "this number of teaspoons for this number of years of age." I calculate scripts by milligrams per kilogram and keep a bathroom scale in my office to capture each child's weight. I write it onto their prescription so that the pharmacist can double check my calculation as an additional safety feature, math not being my strong point at the end of a hectic day.

How many cases of "amoxil allergy" might be due to overdosing I cannot say, but as the father of modern toxicology, Paracelsus, said: "The dose makes the poison."—Dr. Ramon Salazar, family physician, Wolfville, N.S.

Want to share a clinical tip from your practice? Please limit the text to approximately 200 words and email it to andrew.skelly@medicalpost.rogers.com.

Do your patients feel like prisoners to their symptoms of **Generalized Anxiety Disorder?**

At Week 9, Cymbalta® 60 mg once daily:¹

- Significantly improved HAMA total score vs. placebo (mean treatment difference -4.4 vs. placebo, $p < 0.001$);²
- Significantly improved the Sheehan Disability Scale (SDS) work/school score vs. placebo (mean change from baseline -2.62 vs. -1.08 placebo; least squares mean treatment difference -1.48 vs. placebo, $p \leq 0.001$, secondary endpoint).^{2,3}

¹ A 9-week, multicenter, randomized, double-blind, fixed-dose, placebo-controlled study involving patients at least 18 years of age, meeting DSM-IV criteria for GAD. Patients were randomized to receive placebo (n=175), duloxetine 60 mg QD (n=168) or duloxetine 120 mg QD (n=170). The primary efficacy measure was mean change from baseline in HAMA total score vs. placebo. Treatment difference was determined by calculating the difference between mean change in anxiety scores at endpoint between Cymbalta® and placebo arms. Baseline mean HAMA total score = 25.3.^{1,3}

² Cymbalta® Product Monograph, Eli Lilly Canada Inc., May 7, 2014. ³ Koponen H, Allgulander C, Erickson J, et al. Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for the primary care physicians. *Primary Care Companion J Clin Psychiatry* 2007;9:100-107.

Member
R&D PAAB
© Eli Lilly Inc., Toronto, Ontario, M1N 2E8
© Licensed user of trademark owned by Eli Lilly and Company.
1-866-364-4043 | www.lillyinteractive.ca
CACYM00203a

Cymbalta® DELAYED
RELEASE
duloxetine HCl CAPSULES

Lilly